IPP Bureau
Dr. Mandaviya emphasizes on ‘Jan Bhagidari’ to popularise organ donation
By IPP Bureau - September 05, 2022
The purpose of the conclave was to discuss the present situation of body-organ-eye donation in India and find solutions to the challenges ahead in future
Ginkgo Bioworks appoints Dr. Behzad Mahdavi as Sr. VP of Biopharma Manufacturing & Life Science Tools
By IPP Bureau - September 03, 2022
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
USFDA approves first treatment option for generalized pustular psoriasis flares in adults
By IPP Bureau - September 03, 2022
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Ashland to expand bioresorbable polymers capacity in Ireland
By IPP Bureau - September 02, 2022
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Centre grants approval of three Bulk Drug Parks
By IPP Bureau - September 02, 2022
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
Infosys completes acquisition of BASE life science
By IPP Bureau - September 02, 2022
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
NATCO Pharma to sell stake in Nativita and assets of Pharma division
By IPP Bureau - September 02, 2022
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
Kimia Biosciences unveils new logo, new website
By IPP Bureau - September 02, 2022
USFDA inspection at Alembic Pharmaceuticals Injectable Facility (F-3) at Karkhadi
By IPP Bureau - September 02, 2022
Zydus receives final approval from USFDA for two tablets
By IPP Bureau - September 01, 2022
The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04
US FDA issues 17 observations for Biocon Biologics sites
By IPP Bureau - September 01, 2022
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
Stelis Biopharma’s flagship facility receives EIR from USFDA
By IPP Bureau - September 01, 2022
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
Bayer showcases cancer study data at ESMO Congress 2022
By IPP Bureau - September 01, 2022
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert
By IPP Bureau - September 01, 2022
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
By IPP Bureau - September 01, 2022
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
